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The synthetic oestrogens diethylstilboestrol, hexoestrol and 17 a-ethynyloestradiol are known to be carcinogenic, yet they all exert antioxidant 
properties in vitro in that they are good inhibitors of iron ion-dependent lipid peroxidation. In rat liver microsomes incubated with Fe(III)-ascorbam 
or Fe(III)-ADP/NADPH and also in ox-brain phospholipid liposomes incubated with Fe(III)-ascorbate; the overall order of effectiveness of the 
compounds tested as inhibitors of lipid peroxidation was diethylstilboestrol > hexoestrol > 17 u-ethynyloestradiol >4-hydroxytamoxifen > 17 
/I-oestradiol > tamoxifen. Compounds acting as antioxidants towards lipids may also exert pro-oxidant effects towards other molecules uch as 
DNA and thus must never be assumed to be safe for human use. 
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1. INTRODUCTION 
Tamoxifen is used extensively in the treatment of 
breast cancer [l-4] and is now being assessed in clinical 
trials as a prophylactic agent against this disease [5-91. 
However, before tamoxifen became available dieth- 
ylstilboestrol, a non-steroidal synthetic oestrogen, was 
the primary hormonal treatment in postmenopausal 
women [lo]. Furthermore, diethylstilboestrol has been 
extensively used as an antiandrogenic agent for the 
treatment of patients with prostatic carcinoma [11,12]. 
Unfortunately, diethylstilboestrol is also a known trans- 
placental carcinogen in humans [13]. The incidence of 
genital tract cancer increased significantly in the daugh- 
ters of women treated with large doses of diethylstilboe- 
strol for the stabilization of pregnancies [14]. Further- 
more, there is clear evidence that administration of di- 
ethylstilboestrol in large doses during pregnancy in- 
creases the subsequent risk of breast cancer and that 
diethylstilboestrol increases the risk of testicular cancer 
in males exposed in utero [14]. In addition, diethylstil- 
boestrol and synthetic steroidal oestrogens uch as 17 
a-ethynyloestradiol, the oestrogenic component of 
many contraceptive medications, can induce tumours in 
laboratory animals at high doses [15,16]. Although the 
exact mechanism of their carcinogenicity is unclear, 
damage to DNA bases by free radicals arising from the 
metabolism and redox cycling of these compounds may 
be involved [17-211. There is increasing interest in the 
role of oxidant DNA damage in carcinogenesis [ 17-221. 
We have already observed that tamoxifen, which is 
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structurally related to diethylstilboestrol (and its deriva- 
tive hexoestrol) and 17 /I-oestradiol (related to 17 a- 
ethynyloestradiol) can exert antioxidant effects in vitro, 
in that they inhibit metal ion-dependent lipid peroxida- 
tion in a range of membrane systems [23-261. We, there- 
fore, decided to test diethylstilboestrol, its derivative 
hexoestrol and also the synthetic oestrogen 17 a-ethyny- 
loestradiol (structures shown in Fig. 1) in similar sys- 
tems. The results are compared with those obtained for 
tamoxifen, its 4-hydroxy metabolite and 17 j&oestradiol 
and are discussed in relation to both the carcinogenic 
and anticancer actions of diethylstilboestrol and related 
compounds. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Diethylstilboestrol, hexoestrol, 17 cc-ethynyloestradiol, 17jkestra- 
diol, tamoxifen and ox-brain phospholipids were from the Sigma 
Chemical Co. (Poole, UK). 4-Hydroxytamoxifen was kindly donated 
by ICI Pharmaceuticals (Macclesfield, UK). All other reagents were 
of the highest quality from the Sigma Chemical Co. (Poole, UK) or 
from BDH Ltd. (Dagenham, UK). 
2.2. Preparation and peroxidation of microsomes and liposomes 
Rat liver microsomes were prepared from the livers of adult male 
rats by standard differential-centrifugation techniques as described in 
[271. Ox-brain phospholipid liposomes were prepared as described 
previously [25]. 
Microsomal and liposomal lipid peroxidation in the presence of 
Fe(II1) and ascorbate or ADPMADPH, was measured by the forma- 
tion of thiobarbituric acid-reactive substances (TBARS) as described 
previously [22]. The reaction mixtures (final volume of 1.0 ml) con- 
tained either microsomes (0.25 mg of microsomal protein) or li- 
posomes (0.5 mg in 0.1 ml of phosphate buffered saline at pH 7.4); 10 
mM KH,PO,-KOH buffer pH 7.4 was used for microsomal assays and 
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phosphate-buffered saline pH 7.4 was used for liposomal assays; 5 ~1 
of ethanol or test compound dissolved in the same volume of ethanol 
was added. Peroxidation was started by adding aqueous olutions of 
FeCl, (0.1 ml) and ascorbate (0.1 ml) to give a final concentration of 
100 PM of each. In some experiments, microsomal lipid peroxidation 
was started by the addition of FeCI, (100 ,uM), ADP (1.7 mM) and 
NADPH (0.4 mM) to give the final concentrations tated. Freshly 
prepared ADP and FeCl, solutions were premixed just before addition 
to the reaction mixture. Ascorbate or NADPH were added to start the 
reaction, and incubations were carried out at 37°C for 20 min (unless 
stated otherwise). The reactions were terminated by the addition of 
100 pl BHT (butylated hydrox~ol~ne: 0.2% w/v) dissolved in ethanol 
to suppress fwther peroxidation during the heating stage of the TBA 
reaction. The amount of lipid peroxidation was determined by the 
TBA test [27]. HCl (0.5 ml, 25% v/v) was added to each reaction 
mixture, followed by 0.5 ml of thiobarbituric acid solution (1% w/v in 
50 mM sodium hydroxide) and heating at SO*C for 30 min. The 
chromogen was extracted with 2 ml of butan-l-o1 and the AJ3* of the 
upper (organic) layer was measured. 
3. RESULTS 
Diethylstilboestroi, hexoestrof, 17 a-ethynyloestra- 
diol, 17 JSoestradiol, tamoxifen or ~hy~ox~amox~en 
i Do” 
..XzYY 
DIETHYLSTILBOESTROL 
JQffPon 
HEXOESTROL 
on 
, 
I / 
fl HO 0 
17 p- OESTRADIOL 
, ““_ C3CH 
@ no O 
17 ~-ETHYNYLO~STRADIoL 
R, 
<I 
& 
‘I ’ 
:! 
R, ’ &% 
TANOXIFEN R1=li, K,=Ooi,r:ll2N(Cil3)2 
L-HYDROXYTAMOXIFEN Rl=CH, K2=DCH2CH2N(CH3f2 
Fig. 1. Structures of ~ethylstilb~strol, hexoestrol, 17 a-ethynyloe- 
stradiol, 17 @estradiol, tamoxifen and ~hydroxyt~o~fen. 
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Fig. 2. Concentration-dependent i hibition of iron-ion dependent 
lipid peroxidation induced by Fe(IH)-ascorbate in rat liver micro- 
somes. (A) diethylstilboestrol, (m) hexmstrol, (A) 17 a-ethynyloestra- 
diol, (0) 17 /kestradiol, (r) tamoxifen, (0) ~hydrox~o~fen. Re- 
sults are mean k SD., p1= 3-6 tests. 
were each added to rat liver microsomes or ox-brain 
phospholipid liposomes at micromolar concentrations, 
in the range O-30 PM, dissolved in ethanol. Ethanol 
itself when used at a final concentration of 0.5% (v/v) 
had no effect on microsomal or liposomal lipid peroxi- 
dation. 
Fig. 2 shows that when microsomes were incubated 
with Fe(III)-ascorbate, diethylstilboestrol and hexoe- 
strol were powerful inhibitors of peroxidation, with 
very low ICM values (Table I). 17 ~-~th~yl~stradiol 
and 4-hydroxy~o~fen were of similar effectiveness 
and both were more effective than 17 /Loestradiol and 
much more effective than tamoxifen. These differences 
in potency are reflected in their ICSO values (see Table 
I). Table I shows that each of the compounds tested 
appeared to be of similar effectiveness whether micro- 
somal peroxidation was started by adding Fe(III)-as- 
corbate or Fe(III)-ADPLNADPH, except that tamox- 
ifen was more effective in the Fe(III)-ascorbate system, 
as observed previously [23]. The time courses of perox- 
idation in the presence of these compounds, at their ICSO 
~on~ntrations (see Fig. 3) show that they inhibited mi- 
crosomal lipid peroxidation throughout the incubation 
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Table I 
ICsc values for the inhibition of microsomal and liposomal ipid perox- 
idation by diethylstilboestrol, hexoestrol, 17 a-ethynyloestradiol, 17 
j?-oestradiol, tamoxifen and 4-hydroxytamoxifen 
CompoundJDrug systems 
Microsomal 
FeIIIiasc FeIII-ADPI 
NADPH 
UM) QM) 
Liposomal 
FeIIYasc 
01M) 
Diethylst~~~ol 1 1 2.5 
Hexoestrol 1.5 1.25 2.15 
17 ff-Eth~yl~stradiol 2.5 2.75 4 
17 /I-Oestradiol 5 5 5 
Tamoxifen 10.5 23.25 28.75 
4-Hydroxytamoxifen 3 4.25 3.25 
asc, ascorbate. Values are deduced from the graphs shown in Figs. 2 
and 4 in which each point represents the mean f SD. of 3-6 and 4-8, 
respectively, separate assays. 
period: there was no clear evidence of a lag period fol- 
lowed by an acceleration of peroxidation to the control 
rate. 
Fig. 4 shows that when liposomes were incubated 
with Fe(III)-ascorbate, diethylst~boestrol and hexoe- 
strol were approximately equally potent as inhibitors of 
lipid peroxidation and were more effective than 4-hy- 
droxytamoxifen, 17 a-ethynyloestradiol, 17 j?-oestra- 
diol or tamoxifen. Tamoxifen was, as in the microsomal 
system, the least effective compound tested. This is also 
0.7 
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Fig. 3. Tie course of microsomal lipid peroxidation induced by 
Fe(II1) and ascorbate: the effect of test compounds added at their IC,, 
concentrations. (0) control (ethanol only added), (A) 1 PM diethylstil- 
boestrol, (a) 1.5 ,&I hexoestrol, (A) 2.5 PM 17 c+ethynyloestradiol, 
(0) 5 PM 17 /I-oestradiol, (v) 10.5 PM tamoxifen, (e) 3 PM 4-hy- 
droxytamoxifen. Results shown are the means of duplicate determina- 
tions. Concentrations quoted are the final concentrations in the reac- 
tion mixtures. 
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Fig. 4. Concentration-dependent i hibition of iron-dependent lipid 
peroxidation induced by Fe(III)-ascorbate in ox-brain phospholipid 
hposomes. (A) Diethylstilboestrol, (u) hexoestrol, (A) 17 o-ethynyloe- 
stradiol, (0) 17 &oestradiol, (I) tamoxifen, (0) 4-hydroxytamoxifen. 
Results are mean -I SD., n = 4-8 tests, 
reflected in the IC, values of the compo~ds (Table I)_ 
Fig. 5 shows the time-courses of liposomal lipid perox- 
idation, again indicating that the compounds excerted 
inhibitory effects throughout the incubation. 
Control experiments howed that none of the com- 
pounds tested interfered with the TBA test, in that no 
inhibition was observed when the compounds were 
added with the TBA reagents instead of at the beginning 
of the incubations. 
4. DISCUSSION 
These results show that diethyls~boestrol, hexoestrol 
and 17 ~-eth~yl~stra~ol are all powerful antioxi- 
dants, in that they inhibit iron ion-dependent lipid per- 
oxidation in microsomal and liposomal systems. In rat 
liver microsomes peroxidized with Fe(III)-ascorbate, die- 
thylstilboestrol was the most effective inhibitor of lipid 
peroxidation of the compounds tested and the overall 
order of effectiveness was diethylstilboestrol > hexo- 
e&01> 17 a-ethynyloestradiol > 4hydroxytamoxiGen > 17 
jkestradiol > tamoxifen. These compounds had a sim- 
ilar order of effectiveness when the microsomes were 
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strol, (H) 2.75 PM hexoestrol, (A) 4pM 17 a-ethynyloestradiol, (0) 5 
PM 17 /.I-oestradiol, (T) 28.75 PM tamoxifen, (0) 3.25 PM 4-hy- 
droxytamoxifen. Results shown are the means of duplicate determina- 
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peroxidized with Fe(III)-ADFYNADPH, and also in a 
much simpler lipid system, ox-brain phospholipid li- 
posomes, peroxidized with Fe(III)-ascorbate. The 
ethynyl group possessed by 17 a-ethynyloestradiol, but 
not 17 /%oestradiol (see Fig. I), appears to make it a 
somewhat more effective antioxidant than 17 /?-oestra- 
diol and this may reflect an increase its lipophilic nature 
compared to 17 p-oestradiol. Diethylstilboestrol and 
hexoestrol were similarly potent as antioxidants even 
though they differ structurally in that diethylstilboestrol 
has a double bond, which holds it in a particular config- 
uration analogous to ring B in the steroid nucleus (see 
Fig. 1). 
The time-course experiments uggest hat diethylstil- 
boestrol, hexoestrol and 17 cc-ethynyloestradiol do not 
exert their antioxidant action via a chain-breaking 
mechanism, even though hydroxy groups with poten- 
tially donatable hydrogen atoms are present (see Fig. 1). 
There was no clear evidence of a lag period followed by 
an acceleration of peroxidation to the control rate that 
is usually observed with chain-breaking antioxidants. 
Perhaps these compounds act, in whole or in part, by 
stabilizing membranes against peroxidation [24,28]. We 
have suggested previously that this mechanism of anti- 
oxidant action of tamoxifen via decreased membrane 
fluidity may contribute to its known oestrogen receptor- 
independent anticancer action by antagonizing cell divi- 
sion in cancer cells [25,28] and a similar action is possi- 
ble for diethylstilboestrol. 
There is considerable current interest in the role of 
antioxidants as food additives and therapeutic agents 
(reviewed in [29-311). However, such compounds are 
often styled as ‘antioxidants’ merely on the basis of 
ability to inhibit lipid peroxidation. The compounds 
studied in this paper, diethylstilboestrol, hexoestrol and 
17 a-ethynyloestradiol, clearly illustrates how some 
compounds can be powerful inhibitors of lipid peroxi- 
dation whilst actually accelerating oxidative damage to 
DNA via their metabolism [17-211 and causing cancer 
in vivo. The characterization of antioxidants for thera- 
peutic and food use, whether they are synthetic or of 
natural origin, should include much more than just 
studies upon lipids [31-341. 
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